Navigation Links
BMP Sunstone Announces Exchange Offer of $10.7 Million of Outstanding Secured Notes

PLYMOUTH MEETING, Pa., Jan. 21 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company'') today announced the completion of the exchange of approximately $10.7 million in principal amount of the Company's outstanding 10.0% Secured Promissory Notes due May 1, 2009 (the ''Original Notes''), by issuing new 12.5% Secured Promissory Notes, due July 1, 2011, in the same principal amount (the ''New Notes'').

New Notes shall be convertible into common shares of the Company, in whole or in part, any time after May 15, 2009. The Conversion Price shall be equal to the lesser of $5.00 or 115 percent of the sale price per common share in a Qualified Offering, as will be further described in a Form 8-K to be filed by the Company.

David Gao, Chief Executive Officer of BMP Sunstone, commented, ''Today we have significantly increased our financial flexibility so that we can put cash to work to grow our business, integrate our recent acquisitions, launch new products and navigate effectively in China's dynamic healthcare marketplace. Our ability to extend the maturity on some of our outstanding debt, during these unprecedented capital market conditions, speaks to the belief our investors share in BMP Sunstone's long-term prospects."

Additionally, BMP Sunstone today announced financial guidance for the full year 2009. Revenue is anticipated to reach $150 to $160 million, and non-GAAP net income is projected to be between $10 million and $13 million. The Company reconfirmed that for the year 2008, revenue is expected to reach $110 to $120 million, and non-GAAP net income is expected to be in the range of $6.0 to $7.0 million.

David Gao, Chief Executive Officer of BMP Sunstone, stated, ''We expect 2009 to be another record year for our Company, with over 35% growth of revenue calculated at the low end of our guidance ranges for 2008 and 2009. In addition, based on our non-GAAP guidance at the low end of the ranges, we expect over 65% growth of profitability for 2009 as compared to 2008. Just two years ago, we successfully transformed BMP Sunstone from a low margin distribution business into a high margin OTC and prescription specialty pharmaceutical company, and our guidance for 2009 reflects a more mature, diversified company with significant ability to drive shareholder value.''

Gao continued, ''Our 2009 financial guidance reflects sales and marketing expansion in China resulting from continued performance at all of our business units, especially at Sunstone, and reflects operational synergies resulting from acquisitions the Company completed in 2008. In 2009, we expect all of our business units to be profitable and to outperform the market growth. Additionally, our in-license business at Beijing Medpharm will start contributing to the Company's bottom line in 2009, which will mark a significant milestone in the Company's business development.''

Non-GAAP net income excludes stock based compensation, amortization related to acquisitions and other non-cash expenses. GAAP net loss is expected to be in the range of $3.6 million to $4.6 million for the year 2008 and net income in the range of $3.0 million to $6.0 million for the year 2009. The reconciling items between GAAP net income and non-GAAP net income are itemized in Table 1 within this press release.

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Currently this portfolio includes eight products under exclusive multi-year licenses for China, primarily focused on women's health and pediatrics. The Company also owns Sunstone Pharmaceutical Co. Ltd., which manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold through approximately 50,000 pharmacies in China. The Company also provides pharmaceutical distribution services through its subsidiaries in Beijing and Shanghai, and through its affiliate, Guangzhou Pharmaceuticals Corp. The Company has its main office in Beijing, with a US office in Plymouth Meeting, PA. For more information, please visit .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the Company's revenue, net income and profitability guidance for 2008 and 2009, the long-term prospects of the Company and the Company's intent and ability to enhance its capabilities and realized additional opportunities. These statements are subject to uncertainties and risks including, but not limited to, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    BMP Sunstone Corporation
     Fred M. Powell
     Chief Financial Officer
     Tel: +1-610-940-1675

    Integrated Corporate Relations, Inc.
     Ashley M. Ammon and Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)

    Table 1

    (US $M)                                         2009            2008

    GAAP Net Income (Loss)                       $3.0 - 6.0     ($4.6 - 3.6)

    Adjustment                                        $7.00          $10.60

    Non GAAP Net Income                       $10.0 - $13.0     $6.0 - $7.0

SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BMP Sunstones Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
2. BMP Sunstone to Report First Quarter 2008 Financial Results
3. BMP Sunstone Announces Participation in May Investor Conferences
4. BMP Sunstone Donates RMB 1.2 Million to Earthquake Relief
5. BMP Sunstone Reports First Quarter 2008 Financial Results
6. BMP Sunstone Announces Participation in June Investor Conferences
7. BMP Sunstone Announces Official Launch of Ferriprox in PRC
8. BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd
9. BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co.
10. BMP Sunstone to Report Third Quarter 2008 Financial Results
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... serious problem that can often be fatal. Methadone has ... addicts. However, the major concern in treating heroin addicts ... is one reason methadone therapy is usually only given ... that an alternative drug therapy combined with psychosocial treatment ...
... researchers are currently testing the safety of hypothermia ... injury. Hypothermia treatment has been shown to be ... but its effectiveness in treating children with traumatic ... decreases inflammation, excitotoxicity (excessive neurotransmitters released with injury ...
... of skin cancer and it has been shown through previous ... sunlight, whose UV rays cause damage to DNA that triggers ... are more prone than others to melanoma. Researchers have now ... people with melanoma that those with fair skin// have lowered ...
... Affective Disorder(SAD) is not all that well understood, but ... sunlight in the winter months. Winter depression involves suffering ... days get longer and nights get shorter. Other SAD ... sleeping for longer than usual. Researchers have now found ...
... hospital in Kolkatta, India recently received a patient, a two-month-old ... suffering from a rare disease caused due to a deficiency ... of 10 million children. Doctors said that the baby was ... On detection the baby, a boy child, was found to ...
... time to its ultraviolet rays, has always been said to be ... shown that even moderate sun exposure can result in moles that ... to sun has been shown as the main risk factor for ... rarest type of skin cancer, is much weaker. It has however, ...
Cached Medicine News:
(Date:10/8/2015)... Oct. 8, 2015  Clariant, a world leader in specialty ... facility in Belen, New Mexico , has ... including desiccant canisters and packets and other ... plant is the second Clariant site – the first in ... the ISO 15378:2011 standards, following only the Clariant manufacturing facility ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
(Date:10/8/2015)... a clinical stage drug development company focused on advancing ... today the commencement of the US arm of an ... acebilustat, in patients with cystic fibrosis (CF). The study ... the United States and European Union, ... 2016. This landmark clinical trial testing once-daily oral acebilustat ...
Breaking Medicine Technology:
... Texas, Dec. 2, 2010 Ascension Orthopedics, Inc., ... another implantation of the TITAN™ Modular Total Shoulder. ... at Bucks County Specialty Hospital in Bensalem, Pennsylvania. ... postoperative x-rays showed a very anatomic replacement.  The ...
... 2, 2010 Medical devices, biotechnology and IT products ... will present to United States investors and the business ... business and investment opportunities. (Logo: ... successful Chilean Small and Medium Enterprises (SMEs) was selected ...
Cached Medicine Technology:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: